Elotuzumab
Empliciti · Anti-SLAMF7 mAb
Kidney-neutral antibody; unchanged PK in severe impairment and dialysis; no renal dose adjustment.
Anti-Claudin-18.2 monoclonal antibody
Vyloy · Zolb
Anti-Claudin-18.2 monoclonal antibody · approved 2024 · 4 citations
Describes how this page is sourced, not how dangerous the drug is. Thinly sourced means fewer of the sourcing signals are met — not that the agent is kidney-safe. A rule-based summary, not a formal certainty appraisal.
A Claudin-18.2 antibody whose renal risk is indirect — severe nausea and vomiting driving prerenal AKI.
Atlas fields gathered in one place, each linked to the section with its full text and sources. Educational, not medical advice.
Signature lesion
Direct nephrotoxicity is not a recognized feature. The defining, dose-limiting toxicity in the pivotal SPOTLIGHT and GLOW trials is severe nausea and vomiting (an on-target effect on gastric mucosa), which can cause volume depletion and prerenal acute kidney injury. A quantified renal-injury rate is not reported; the renal risk is mechanistic/indirect.Source: Shah et al., Nat Med 2023 (GLOW); nausea/vomiting-driven volume depletion
Prerenal AKI around infusions, especially the first cycles, tracking the nausea/vomiting peak.
Distilled from: “Around infusions, especially the first cycles, tracking the nausea/vomiting peak.”
This agent's defining kidney lesion — its #1 signature. Cited incidence is shown where a citable figure exists; otherwise the tier stands qualitatively.
Renal hypoperfusion from capillary leak and cytokine storm — IL-2 and CAR-T cytokine release syndrome.
Chimeric IgG1 monoclonal antibody targeting Claudin-18.2, a tight-junction protein exposed on gastric and gastroesophageal adenocarcinoma cells. Binding triggers antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. Given with chemotherapy (e.g., CAPOX/mFOLFOX6) for CLDN18.2-positive, HER2-negative locally advanced/metastatic gastric or GEJ adenocarcinoma.
Vasculature / Endothelium
Glomerular & peritubular capillaries
4 primary references — trials, cohorts, mechanism, and reviews. Citation metadata via PubMed / NLM.
Primary (non–case-report) references per year — a proxy for how actively the agent's renal literature is accruing. Recent years are highlighted. Reflects curation depth, not a systematic bibliometric count.
Everything below is FAERS — adverse events someone chose to report, about 1,525 of them for this agent. Nobody counts the patients who were fine, so none of these numbers is an incidence, a risk, or a rate: they describe what gets reported, shaped by a drug's fame, its indication, and who was watching. How these numbers work.
Only significant signals appear (95% CI lower bound above 1) — a phenotype missing here was tested and did not reach significance, except Prerenal / Hemodynamic AKI, Pseudo-AKI, Renal Cysts, Chronic Interstitial Nephropathy — outside the clinician-reviewed MedDRA term map, never queried — and ATN and AIN, queried but biopsy-bound: real cases are filed as generic “acute kidney injury”, so their absence is not a negative. As of 2026-11-15.
What reporting says about this profile's documented lesions
Reported with a death outcome
178 of 1,525 reports
Reported with hospitalization
515 of 1,525 reports
Reports per year
Reports received per year, 2015–2026 · most recent year is partial.
Bars rank systems by summed reaction-term mentions (a report counts once per term it names) — an ordinal “more vs less reported” cue, not a tally of distinct reports. Renal & urinary first. As of 2026-11-15.
Each recommendation below is this atlas's faithful summary of the source, not a quotation from it — follow the PubMed link for the wording the society published. Summaries may be superseded; consult the current full text and individualize to the patient.
General onco-nephrology references
Where Zolbetuximab sits in nephrotoxicity space — each dot is an anti-cancer agent, positioned so neighbors share a kidney-injury phenotype. Its 6 closest are filled and lead to a numbered marker, matching the numbered cards below.
Empliciti · Anti-SLAMF7 mAb
Kidney-neutral antibody; unchanged PK in severe impairment and dialysis; no renal dose adjustment.
Lymphir · Immunotoxin (IL-2–diphtheria)
Capillary-leak syndrome → prerenal AKI.
Kimmtrak · Bispecific T-cell engager (gp100×CD3 ImmTAC)
CRS-driven hypotension → prerenal AKI early in dosing; uveal melanoma.
Lonsurf · Oral fluoropyrimidine + TP inhibitor
Tipiracil is renally cleared; reduced GFR raises exposure and early severe neutropenia; dose-reduce in renal impairment.
Ojemda · Type II pan-RAF (BRAF) inhibitor
2024 pediatric glioma RAF inhibitor; creatinine rise.
Modeyso · Imipridone (ONC201; DRD2/ClpP)
2025 imipridone for H3 K27M glioma; renally well tolerated — QT prolongation, not nephrotoxicity, is the safety focus.
Nearest agents by kidney-injury phenotype (shared injuries, nephron target, severity, class) — a similarity approximation, not a claim of shared drug identity or mechanism.
Same-class agents ordered by their documented kidney-injury profile — atlas severity, an acute-kidney-injury FAERS signal, and how many injury types each is documented to cause. Agents nearer the top carry the lighter documented renal profile. Agents sharing a number are tied on all three. An agent marked FAERS n/a has too few reports to test, so its place rests on severity and injury breadth alone.
A comparison of documented kidney-injury data within one drug class — not a substitution recommendation. Efficacy, indication, and non-renal toxicity differ between these agents and are out of scope here. Educational only, not medical advice.